Weekly round-up: Strong media coverage for radiopharmaceutical company Ariceum Therapeutics after early success in NHS brain tumour trial
Remarkable results from the start of a trial testing Ariceum Therapeutics’ experimental radiopharmaceutical drug ATT001 in patients with recurrent glioblastoma brain cancer generated strong coverage in the UK’s national media this week. Meanwhile Ariceum’s Chief Operating Officer Greg Mullen featured in an Optimum TV episode, where he explained the highly targeted radiopharmaceutical approach, called Auger […]